Personalized drug rescue and repositioning

We are a service provider company working on our Personalized Drug Rescue and Repositioning software suite, which unifies data fusion and biomarker selection technologies in a sequential decision theoretic framework. Our aim is to support the identification of novel indications or novel contexts for failed candidates and to extend the life-cycle of marketed drugs.

Drug repositioning is a traditional technique, which was mainly guided by serendipitous observations for decades. The following factors all contribute to its recent popularity: success stories, the productivity gap, a shortened pharma pipeline, polypharmacy (multiple targets for a given drug), network pharmacology (multiple factors, pathways behind diseases), and improved in silico data integration and fusion methodologies.



Pharmacogenetics is a similarly well-known concept for decades, but recent dramatic improvements in molecular biological measurement technologies revolutionized this area leading to the concepts of pharmacogenomics and personalized medicine. The personal genome combined with improved electronic health records using more refined phenotypical descriptors for the disease, efficacy, and side-effects opens up new possibilities for the development of niche-drugs. Besides cost-effective measurements, the improved biomarker selection and population stratification methods coping with interactions, temporality, and interventions, and also supporting functional and pathway level interpretation are equally crucial to reach these goals.



We have developed our Personalized Drug Rescue and Repositioning software suite, to cope with these two challenges and to utilize their synergy, which unifies systems-based biomarker analysis and similarity-based data fusion technologies in a sequential decision theoretic framework.